ReviewDrug discovery today2016
Recent developments in using mechanistic cardiac modelling for drug safety evaluation.
Review in Drug discovery today, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed.
- QT interval prolongation: clinical assessment, risk factors and quantitative pharmacological considerations.Journal of pharmacokinetics and pharmacodynamics · 2025Review
- Ion channel traffic jams: the significance of trafficking deficiency in long QT syndrome.Cell discovery · 2025Review
- Informing Hazard Identification and Risk Characterization of Environmental Chemicals by Combining Transcriptomic and Functional Data from Human-Induced Pluripotent Stem-Cell-Derived Cardiomyocytes.Chemical research in toxicology · 2024Article
- Global Sensitivity Analysis of Four Chamber Heart Hemodynamics Using Surrogate Models.IEEE transactions on bio-medical engineering · 2022Article
- The health digital twin to tackle cardiovascular disease-a review of an emerging interdisciplinary field.NPJ digital medicine · 2022Review
- A Quantitative Systems Pharmacology Perspective on the Importance of Parameter Identifiability.Bulletin of mathematical biology · 2022Article
- Towards patient-specific prediction of conduction abnormalities induced by transcatheter aortic valve implantation: a combined mechanistic modelling and machine learning approach.European heart journal. Digital health · 2021Article
- The 'Digital Twin' to enable the vision of precision cardiology.European heart journal · 2020Article
- Use of Patient Health Records to Quantify Drug-Related Pro-arrhythmic Risk.Cell reports. Medicine · 2020Article
- The fickle heart: uncertainty quantification in cardiac and cardiovascular modelling and simulation.Philosophical transactions. Series A, Mathematical, physical, and engineering sciences · 2020Article
- Review
- Classifying Drugs by their Arrhythmogenic Risk Using Machine Learning.Biophysical journal · 2020Article
- General Principles for the Validation of Proarrhythmia Risk Prediction Models: An Extension of the CiPA In Silico Strategy.Clinical pharmacology and therapeutics · 2020Article
- Quantitative Systems Pharmacology Models for a New International Cardiac Safety Regulatory Paradigm: An Overview of the Comprehensive In Vitro Proarrhythmia Assay In Silico Modeling Approach.CPT: pharmacometrics & systems pharmacology · 2019Review
- Cardiovascular disease models: A game changing paradigm in drug discovery and screening.Biomaterials · 2019Review
- Modeling cardiac complexity: Advancements in myocardial models and analytical techniques for physiological investigation and therapeutic developmentAPL bioengineering · 2019Review
- Article
- Harvesting the promise of AOPs: An assessment and recommendations.The Science of the total environment · 2018Review
- Validation and Trustworthiness of Multiscale Models of Cardiac Electrophysiology.Frontiers in physiology · 2018Review
- Modelling variability in cardiac electrophysiology: a moment-matching approach.Journal of the Royal Society, Interface · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
On the tenth anniversary of two key International Conference on Harmonisation (ICH) guidelines relating to cardiac proarrhythmic safety, an initiative aims to consider the implementation of a new paradigm that combines in vitro and in silico technologies to improve risk assessment. The Comprehensive In Vitro Proarrhythmia Assay (CiPA) initiative (co-sponsored by the Cardiac Safety Research Consortium, Health and Environmental Sciences Institute, Safety Pharmacology Society and FDA) is a bold and welcome step in using computational tools for regulatory decision making. This review compares and contrasts the state-of-the-art tools from empirical to mechanistic models of cardiac electrophysiology, and how they can and should be used in combination with experimental tests for compound decision making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.